CTLA4 and neoplasm: ZM-241385 was tested both alone and in combination with an anti-CTLA4 mAb in a B16F10 mouse melanoma model, and it was found that melanoma-bearing mice treated with ZM-241365 alone showed a marked tumor growth inhibition compared with controls, and the combination therapy showed significant tumor growth delay compared with either controls or each agent alone [55].